In addition to its efficacy in the treatment of melanoma, nivolumab has been shown to exhibit a therapeutic benefit against a wider spectrum of cancers than anti-CTLA-4 immune checkpoint inhibitors. This evidence concerns the gene CTLA4 and melanoma.